IONIS PHARMACEUTICALS INC (IONS)
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business